Fig. 3.
Combination treatment of enzalutamide and metformin did not attenuate 22Rv1 xenograft tumor growth in vivo. (A) Tumor growth curves of 22Rv1-derived xenograft. Precastrated nude mice were inoculated subcutaneously with 22Rv1 cells (2.5 × 106 per mouse) and allowed to grow for 2 weeks. After 2 weeks, the mice were treated with various drugs as described in the Materials and methods section of this article. The sizes of the tumors in each group were measured every 3 days (mean ± SD; n = 13 mice per group). (B) Measurement of tumor weight immediately after harvest. (C) Images of 22Rv1-derived tumors at the end of the study. (D) Measurement of mouse body weight throughout the study. (E) Representative images of H&E staining on formaldehyde-fixed, paraffin-embedded, 22Rv1-derived tumor sections. (F) Representative images of anti-Ki67 immunohistochemistry staining of tumor sections. (G) Representative images of anticleaved caspase-3 immunohistochemistry staining of tumor sections.